Pipeline

Basilea is marketing Toctino® (alitretinoin), the only approved treatment for severe chronic hand eczema unresponsive to potent topical steroids, in Denmark, Finland, France, Germany, Norway, Switzerland and the United Kingdom. Basilea has appointed distributors for Toctino® in other selected European markets, Canada, Israel, Mexico and the Republic of Korea. The company has entered into a global partnership with Astellas Pharma Inc. for Basilea's phase III compound isavuconazole, a potential best-in-class azole antifungal, for the treatment of life-threatening invasive fungal infections. In addition, Basilea is developing ceftobiprole, a late-stage novel anti-MRSA broad-spectrum cephalosporin antibiotic, for the treatment of potentially life-threatening resistant bacterial infections.